We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bio-Rad Honored With Awards

By Biotechdaily staff writers
Posted on 28 Oct 2005
Bio-Rad Laboratories, Inc. (Hercules, CA, USA) has received a Market Leadership Award for drug discovery technologies for the company's KnowItAll ADME (absorption, digestion, metabolism, excretion)/Tox software and databases. The award, from the international consulting firm Frost & Sullivan (Palo Alto, CA, USA), is given to a single company annually that has displayed excellence in all areas of market leadership, including the identification of market challenges, drivers and restraints, as well as strategy development and methods of addressing these market dynamics.

"The company is recognized for excelling in market share, revenue growth rates, and profitability, as well as market and technology innovation,” explained Dr. Amarpreet Dhiman, industry analyst with Frost & Sullivan. "A clear understanding of end-user needs, a commitment to providing outstanding customer service, and the ability to forge productive collaborations have powered the constant expansion of the award recipient's client base.”

Bio-Rad's KnowItAll informatics system for in silico ADME/Tox offers a complete suite of tools for the computer-based prediction of a potential drug's ADME/Tox profile, including one of the largest collections of predictive models, applications to build and validate predictive models, experimental ADME/Tox data, and integrated tools for chemical structure handling, data management, and reporting.

Bio-Rad also received a Product Innovation Award from Frost & Sullivan for ADME/Tox Informatics. Winners are selected on the basis of market participant interviews, end-user surveys, and secondary research. The recipient must also demonstrate innovation by launching a broad line of emerging products and technologies.




Related Links:
Bio-Rad

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Hematology Consumables
Bioblood Devices
New
Clinical Informatics Platform
CLARION™

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
28 Oct 2005  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
28 Oct 2005  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
28 Oct 2005  |   BioResearch